Literature DB >> 22152856

Expression of Wilms tumor 1 gene in a variety of pediatric tumors.

Takaharu Oue1, Shuichiro Uehara, Hiroaki Yamanaka, Yuichi Takama, Yusuke Oji, Masahiro Fukuzawa.   

Abstract

BACKGROUND/
PURPOSE: Wilms tumor 1 (WT1) gene is overexpressed in many types of neoplasms, thus suggesting that WT1 has oncogenic properties. Therefore, WT1 is a molecular target for cancer therapy. The objectives of this study were to evaluate the WT1 gene expression in various pediatric tumors and to elucidate that WT1 can be a target of cancer therapy in pediatric malignancies. PATIENTS AND METHODS: The expression of WT1 protein was examined in 60 cases of primary pediatric tumors. The levels of WT1 messenger RNA (mRNA) expression were examined by a quantitative real-time reverse transcriptase polymerase chain reaction analysis in frozen tissue samples from 56 cases with pediatric tumors.
RESULTS: Immunohistochemical staining revealed that WT1 protein was widely detected in pediatric malignancies. The alveolar subtype of rhabdomyosarcoma showed more intensive staining than the embryonal subtype. The positive rate of the alveolar type was significantly higher than that of the embryonal type. The expression of WT1 mRNA in the tumor samples varied widely. However, no significant correlation was observed between WT1 mRNA expression and clinical factors.
CONCLUSION: The WT1 expression was broadly detected in various pediatric neoplasms. These results indicate that WT1 may therefore be a potentially useful therapeutic target in most of pediatric malignancies.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22152856     DOI: 10.1016/j.jpedsurg.2011.09.004

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

1.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

Review 2.  Targeted immunotherapy for pediatric solid tumors.

Authors:  Lisa M Kopp; Emmanuel Katsanis
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

Review 3.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

4.  Wilms' tumor gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line.

Authors:  Rosalba Parenti; Venera Cardile; Adriana Carol Eleonora Graziano; Carmela Parenti; Assunta Venuti; Maria Paola Bertuccio; Debora Lo Furno; Gaetano Magro
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

5.  Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.

Authors:  Nobuhiro Tsuchiya; Ako Hosono; Toshiaki Yoshikawa; Kayoko Shoda; Kazuto Nosaka; Manami Shimomura; Junichi Hara; Chika Nitani; Atsushi Manabe; Hiroki Yoshihara; Yosuke Hosoya; Hide Kaneda; Yoshiaki Kinoshita; Kenichi Kohashi; Kenichi Yoshimura; Norihiro Fujinami; Keigo Saito; Shoichi Mizuno; Tetsuya Nakatsura
Journal:  Oncoimmunology       Date:  2017-09-27       Impact factor: 8.110

6.  Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation.

Authors:  Adriana Carol Eleonora Graziano; Venera Cardile; Rosanna Avola; Nunzio Vicario; Carmela Parenti; Lucia Salvatorelli; Gaetano Magro; Rosalba Parenti
Journal:  Oncotarget       Date:  2017-02-21

7.  Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.

Authors:  Yu Akazawa; Ako Hosono; Toshiaki Yoshikawa; Hide Kaneda; Chika Nitani; Junichi Hara; Yoshiaki Kinoshita; Kenichi Kohashi; Atsushi Manabe; Miki Fukutani; Masashi Wakabayashi; Akihiro Sato; Kayoko Shoda; Manami Shimomura; Shoichi Mizuno; Yasunari Nakamoto; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2019-11-19       Impact factor: 6.716

8.  Variant profiles of genes mapping to chromosome 16q loss in Wilms tumors reveals link to cilia-related genes and pathways.

Authors:  Eiko Kitamura; John K Cowell; Chang-Sheng Chang; Lesleyann Hawthorn
Journal:  Genes Cancer       Date:  2020-10-06

9.  WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.

Authors:  Shouq Alzaaqi; Norifumi Naka; Kenichiro Hamada; Naoki Hosen; Mizuki Kanegae; Hidetatsu Outani; Mayuko Adachi; Rin Imanishi; Eiichi Morii; Miki Iwai; Jun Nakata; Fumihiro Fujiki; Soyoko Morimoto; Hiroko Nakajima; Sumiyuki Nishida; Akihiro Tsuboi; Yoshihiro Oka; Haruo Sugiyama; Yusuke Oji
Journal:  Oncol Lett       Date:  2022-01-03       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.